Skip to main content
no upcoming events

Please check back with us.

PIPELINE > TRIAL OVERVIEW

Trial Information
Molecule Overview
VEGF Receptor-2 Antagonist
Ramucirumab
Phase
2
Not Enrolling
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor*
Related Resources:
Molecule Overview Trial Enrollment
NCT04145349 show modal icon
Key Inclusion Criteria
  • If in the US, aged 12 months to 29 years. If in the EU, aged 36 months to 29 years and >11 kg at study entry
  • Relapsed, recurrent, or refractory desmoplastic small round cell tumors
  • Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  • Received at least one prior line of systemic treatment (including neoadjuvant/adjuvant chemotherapy), including approved therapies for which the patient is eligible
  • Discontinued all previous treatments for cancer or investigational agents ≥7 days prior to study entry and recovered from select acute effects to grade ≤2 for alopecia and decreased tendon reflex, and to grade ≤1 for all other effects at the time of enrollment||
  • Adequate hematologic and organ function for at least 7 days prior to first dose of study drug||
  • Female participants of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to randomization. Male and female participants must agree to use highly effective contraception for the duration of the study and up to 3 months following the last dose of ramucirumab and vinorelbine, and 12 months following the last dose of cyclophosphamide
Key Exclusion Criteria
  • Eligible for surgical resection at time of enrollment
  • Active infections requiring therapy, including HIV or hepatitis A, B, or C
  • Prior allogeneic bone marrow or solid organ transplant
  • Major surgical, laparoscopic, or significant traumatic injury within 28 days prior to enrollment. Surgical or other wounds must be adequately healed prior to enrollment
  • Evidence of active bleeding, a bleeding diathesis or vasculitis, or a history of significant (grade ≥3) bleeding event, hemoptysis or pulmonary hemorrhage, a DVT or PE requiring medical intervention, or esophageal varices within 3 months prior to enrollment
  • History of central nervous system arterial/venous thromboembolic events, including transient ischemic attack or cerebrovascular accident within 6 months prior to study enrollment, myocardial infarction or unstable angina within the prior 6 months, New York Heart Association (NYHA) grade ≥2 congestive heart failure, serious and inadequately controlled cardiac arrhythmia, significant vascular disease, or clinically significant peripheral vascular disease
  • History of fistula, gastrointestinal ulcer or perforation, or intra-abdominal abscess within 3 months of study enrollment
  • History of hypertensive crisis or hypertensive encephalopathy within 6 months of study enrollment
  • Known hypersensitivity to ramucirumab, cyclophosphamide, vinorelbine, or any of the excipients of the medicinal product
  • Severe liver cirrhosis (Child-Pugh class B or worse), cirrhosis with a history of hepatic encephalopathy, clinically meaningful ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis, or history of hepatorenal syndrome
  • Bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection, Crohn's disease, ulcerative colitis, or chronic diarrhea
  • Urinary outflow obstruction, grade 2 hematuria, or noninfectious cystitis at the time of screening
  • Severe and/or uncontrolled concurrent medical disease or psychiatric illness/social situation that, in the opinion of the investigator, could cause unacceptable safety risks or compromise protocol compliance
  • Prior treatment with/progression on combination cyclophosphamide and vinorelbine regimen; prior treatment with ramucirumab
*
This clinical trial is being conducted globally.
†
Ramucirumab is administered intravenously (IV).
‡
Cyclophosphamide is administered PO.
§
Vinorelbine is administered IV.
‖
Additional criteria apply.
For information on trial enrollment, locations, and more, call 1-800-545-5979.
REQUEST A MEDICAL SCIENCE LIAISON

or visit www.clinicaltrials.gov for more information on this trial